Charles River Laboratories Intl. Inc vs Indonesia Energy Corporation Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $286.38 (market cap $13.46B), while Indonesia Energy Corporation Limited trades at $2.9 (market cap $45.55M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 295.5× Indonesia Energy Corporation Limited's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| CRL | INDO | |
|---|---|---|
Market Cap | $13.46B | $45.55M |
Sector | Health | Energy |
52-Week High | $282.00 | $6.74 |
52-Week Low | $145.57 | $2.49 |
Enterprise Value | $16.30B | $40.92M |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Indonesia Energy Corporation (INDO) trades at $2.89, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company is actively drilling the K-29 well at its Kruh Block, indicating operational progress. Financially, it shows deep losses with a net income margin of -253.4% and negative ROE of -26.95% for 2025, though it beat EPS estimates in Q2 2025. Valuation metrics include a P/S of 21.57 and P/B of 2.32, reflecting high sales multiples amid profitability challenges.
The outlook hinges on successful well outcomes driving future revenue; current analyst consensus is 100% buy, but high execution risks and persistent losses pose significant threats to shareholder value. Investors face volatility from oil price swings and operational delays.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →